Sarah Verhoeff

147 Summary, general discussion and future perspectives REFERENCES 1. Rini BI, Dorff TB, Elson P, et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. The Lancet Oncology. 2016;17(9):1317-1324. 2. Warburg O, Wind F, Negelein E. THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 1927;8(6):519-530. 3. Czernin J, Allen-Auerbach M, Nathanson D, Herrmann K. PET/CT in Oncology: Current Status and Perspectives. Current Radiology Reports. 2013;1(3):177-190. 4. Bailly C, Bodet-Milin C, Bourgeois M, et al. Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture. Cancers (Basel). 2019;11(9). 5. Ivanov S, Liao SY, Ivanova A, et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. The American journal of pathology. 2001;158(3):905-919. 6. van Kuijk SJ, Yaromina A, Houben R, Niemans R, Lambin P, Dubois LJ. Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis. Front Oncol. 2016;6:69. 7. Oosterwijk E, Bander NH, Divgi CR, et al. Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol. 1993;11(4):738-750. 8. Hekman MCH, Rijpkema M, Aarntzen EH, et al. Positron Emission Tomography/Computed Tomography with (89) Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion. Eur Urol. 2018. 9. Sanmamed MF, Chen L. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell. 2018;175(2):313-326. 10. Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat Immunol. 2019;20(11):1425-1434. 11. Ju X, Zhang H, Zhou Z, Wang Q. Regulation of PD-L1 expression in cancer and clinical implications in immunotherapy. Am J Cancer Res. 2020;10(1):1-11. 12. Paijens ST, Vledder A, de Bruyn M, Nijman HW. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol. 2021;18(4):842-859. 13. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9(2):802-811. 14. Patard J-J, Fergelot P, Karakiewicz PI, et al. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. International Journal of Cancer. 2008;123(2):395-400. 15. Lim EA, Drake CG, Mintz A. Molecular imaging for cancer immunotherapy. Immuno-Oncology Technology. 2020;5:1021. 16. Azzi S, Hebda J, GAVARD J. Vascular Permeability and Drug Delivery in Cancers. Frontiers in Oncology. 2013;3(211). 17. Jauw YWS, O’Donoghue JA, Zijlstra JM, et al. (89)Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo. J Nucl Med. 2019;60(12):1825-1832. 18. Broos K, Lecocq Q, Raes G, Devoogdt N, Keyaerts M, Breckpot K. Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy. Theranostics. 2018;8(13):3559-3570. 19. Tang F, Zheng P. Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy? Cell Biosci. 2018;8:34. 20. Callahan MK, Wolchok JD. Recruit or Reboot? How Does Anti-PD-1 Therapy Change Tumor-Infiltrating Lymphocytes? Cancer Cell. 2019;36(3):215-217. 21. Li F, Li C, Cai X, et al. The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis. EClinicalMedicine. 2021;41:101134. 22. Farwell MD, Gamache RF, Babazada H, et al. CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of <sup>89</sup>Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody. Journal of Nuclear Medicine. 2021:jnumed.121.262485. 23. Polverari G, Ceci F, Bertaglia V, et al. 18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival. Cancers. 2020;12(5):1163. 8